<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Ashley Communications</title>
	<atom:link href="http://www.ashleycomms.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.ashleycomms.com</link>
	<description>A unique medical communications company</description>
	<lastBuildDate>Wed, 25 Apr 2012 11:28:56 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>Demonstrating Success in a Rare Cancer</title>
		<link>http://www.ashleycomms.com/2012/01/demonstrating-success-in-a-rare-cancer/</link>
		<comments>http://www.ashleycomms.com/2012/01/demonstrating-success-in-a-rare-cancer/#comments</comments>
		<pubDate>Tue, 31 Jan 2012 13:24:04 +0000</pubDate>
		<dc:creator>Ashley Communications</dc:creator>
				<category><![CDATA[Ashley Communications News]]></category>

		<guid isPermaLink="false">http://www.ashleycomms.com/?p=402</guid>
		<description><![CDATA[Ashley Communications reflect on 2 years supporting Takeda Pharmaceuticals Europe building a presence in oncology throughout Europe, beginning with the launch of Mepact® (mifamurtide) for osteosarcoma. Since in January 2010, Ashley Communications have been working with Takeda Pharmaceuticals Europe delivering &#8230; <a href="http://www.ashleycomms.com/2012/01/demonstrating-success-in-a-rare-cancer/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<p><em>Ashley Communications reflect on 2 years supporting Takeda Pharmaceuticals Europe building a presence in oncology throughout Europe, beginning with the launch of Mepact<sup>®</sup> (mifamurtide) for osteosarcoma.</em></p>
<p>Since in January 2010, Ashley Communications have been working with Takeda Pharmaceuticals Europe delivering a broad range of activities across our core services of medical communications, medical education and medical publications.  The activities the team have recommended and executed have helped Mepact to achieve a strong start in an ultra orphan disease area which has received very little attention over the last 20 years.</p>
<p>Activities delivered have included:</p>
<ul>
<li>Internal launch symposium and training modules</li>
<li>Key Opinion Leader profiling</li>
<li>Advisory Boards, both strategic and clinical</li>
<li>Congress symposia and debates, with newsletters</li>
<li>Mode of action animation for booths and local meetings</li>
<li>Administration videos, in different European languages</li>
<li>Publications, considering the disease area and the place for Mepact as well as broader issues such as the challenges and cost of developing new drugs in small, rare diseases</li>
<li>Expert Opinions in Osteosarcoma (<a title="Expert Opinions " href="http://www.ashleycomms.com/medical-publications/" target="_blank">www.ashleycomms.com/medical-publications/</a>)</li>
<li>Evidence Pack</li>
<li>Mepact Meetings Manager resources for affiliates (<a title="Mepact Meetings Manager resources for affiliates " href="http://www.ashleycomms.com/projects/mepact-meetings-manager/" target="_blank">www.ashleycomms.com/projects/mepact-meetings-manager/</a>)</li>
<li>Speaker Bureau management, providing supporting for affiliates for local meetings</li>
<li>Digital and creative solutions for booths i.e. interactive case studies and video ‘vox pops’</li>
<li>Building relationships with patient advocacy groups.</li>
</ul>
<p>Many of these educational activities will continue in 2012 as Takeda Pharmaceuticals Europe continues to demonstrate their commitment to oncology. With over 100 patients now receiving Mepact, activities will focus on harnessing the experience across Europe to improve awareness and understanding, including the use of patient case studies, a Preceptorship Programme and a standalone meeting.</p>
<p>Ashley Communications now works across the Takeda Pharmaceuticals Europe oncology portfolio including Adectris<sup>®</sup> (brentuximab vedotin) for Hodgkin lymphoma and systemic anaplastic large cell lymphoma, and<strong> </strong>orteronel (TAK-700) for castrate resistant prostate cancer.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ashleycomms.com/2012/01/demonstrating-success-in-a-rare-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New guidance on EACCME accreditation from UEMS</title>
		<link>http://www.ashleycomms.com/2012/01/new-guidance-on-eaccme-accreditation-from-uems/</link>
		<comments>http://www.ashleycomms.com/2012/01/new-guidance-on-eaccme-accreditation-from-uems/#comments</comments>
		<pubDate>Tue, 31 Jan 2012 09:17:31 +0000</pubDate>
		<dc:creator>Ashley Communications</dc:creator>
				<category><![CDATA[Ashley Communications News]]></category>

		<guid isPermaLink="false">http://www.ashleycomms.com/?p=369</guid>
		<description><![CDATA[Ashley Communications welcome the new guidance and increased clarity on how to achieve EACCME accreditation from UEMS on e-learning and live events. For more Information Please view the pdf files below. UEMS Live Events   UEMS Updates CME Criteria &#160;]]></description>
			<content:encoded><![CDATA[<p>Ashley Communications welcome the new guidance and increased clarity on how to achieve EACCME accreditation from UEMS on e-learning and live events. For more Information Please view the pdf files below.</p>
<p><a href="http://www.ashleycomms.com/wp-content/uploads/2012/01/UEMS-Live-Events.pdf" target="_blank">UEMS Live Events</a>   <a href="http://www.ashleycomms.com/wp-content/uploads/2012/01/UEMS-Updates-CME-Criteria1.pdf" target="_blank">UEMS Updates CME Criteria</a></p>
<p>&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ashleycomms.com/2012/01/new-guidance-on-eaccme-accreditation-from-uems/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fresh new look for ashleycomms.com</title>
		<link>http://www.ashleycomms.com/2011/11/fresh-new-look-for-ashleycomms-com/</link>
		<comments>http://www.ashleycomms.com/2011/11/fresh-new-look-for-ashleycomms-com/#comments</comments>
		<pubDate>Mon, 21 Nov 2011 16:16:39 +0000</pubDate>
		<dc:creator>Ashley Communications</dc:creator>
				<category><![CDATA[Ashley Communications News]]></category>

		<guid isPermaLink="false">http://alpha.xssl.net/~ashley/?p=224</guid>
		<description><![CDATA[We are pleased to announce the launch of our brand new Ashley Communications website!  Please take a look around &#38; let us know what you think. The new website has been built to better explain what we do &#8211; and &#8230; <a href="http://www.ashleycomms.com/2011/11/fresh-new-look-for-ashleycomms-com/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<p>We are pleased to announce the launch of our brand new Ashley Communications website!  Please take a look around &amp; let us know what you think.</p>
<p>The new website has been built to better explain what we do &#8211; and that includes a new and updated area specifically for showcasing some of our previous work.  Take a look at the projects page here: <a href="http://www.ashleycomms.com/projects/">www.ashleycomms.com/projects/</a>.</p>
<p>In addition, the website has been built with the future very much in mind &#8211; it uses a technique called Responsive Design to ensure that it looks great &amp; functions well on mobile as well as desktop.</p>
<p>Use the comments form below to let us know what you think!</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ashleycomms.com/2011/11/fresh-new-look-for-ashleycomms-com/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ashley Communications proud to be associated with latest global blockbuster</title>
		<link>http://www.ashleycomms.com/2011/10/ashley-communications-proud-to-be-associated-with-latest-global-blockbuster/</link>
		<comments>http://www.ashleycomms.com/2011/10/ashley-communications-proud-to-be-associated-with-latest-global-blockbuster/#comments</comments>
		<pubDate>Wed, 19 Oct 2011 11:28:35 +0000</pubDate>
		<dc:creator>Ashley Communications</dc:creator>
				<category><![CDATA[Client News]]></category>

		<guid isPermaLink="false">http://alpha.xssl.net/~ashley/?p=57</guid>
		<description><![CDATA[Ashley Communications is proud to be the medical education company associated with Vesicare from Astellas, which has recently been classified as a Global Blockbuster and is the No.1 prescribed drug for overactive bladder in Europe.  Ashley Communications has been responsible &#8230; <a href="http://www.ashleycomms.com/2011/10/ashley-communications-proud-to-be-associated-with-latest-global-blockbuster/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.ashleycomms.com/wp-content/uploads/2011/10/Vesicare.jpg" rel="lightbox[57]" title="Vesicare TM"><img class="size-full wp-image-58 alignleft" title="Vesicare TM" src="http://www.ashleycomms.com/wp-content/uploads/2011/10/Vesicare.jpg" alt="" width="220" height="138" /></a>Ashley Communications is proud to be the medical education company associated with Vesicare from Astellas, which has recently been classified as a Global Blockbuster and is the No.1 prescribed drug for overactive bladder in Europe.  Ashley Communications has been responsible for Vesicare since 2003, taking it through its critical pre-launch, launch and post-launch phases and continue to support Astellas at both a Global and European level.</p>
<p>&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ashleycomms.com/2011/10/ashley-communications-proud-to-be-associated-with-latest-global-blockbuster/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

